<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-19T11:28:09+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-19T08:19:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-19:/s/odtkfYlU2gUMpHmC8dffEw</id>
    <link href="https://mp.weixin.qq.com/s/odtkfYlU2gUMpHmC8dffEw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价HL-085胶囊治疗NRAS突变的晚期黑色素瘤患者的有效性、安全性的单臂、多中心Ⅱ期临床研究</title>
    <updated>2020-12-19T08:19:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-19:/s/sGVJ_ulT00ajVTnqRuiqaQ</id>
    <link href="https://mp.weixin.qq.com/s/sGVJ_ulT00ajVTnqRuiqaQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-18T07:10:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/sXc5og0NawSluHD-3kvkkg</id>
    <link href="https://mp.weixin.qq.com/s/sXc5og0NawSluHD-3kvkkg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】TQB2618注射液在晚期实体瘤患者中的安全性、耐受性及药代动力学I期临床试验</title>
    <updated>2020-12-18T07:10:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/NRE5BmX6bHkmXzX-JlZqlw</id>
    <link href="https://mp.weixin.qq.com/s/NRE5BmX6bHkmXzX-JlZqlw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-17T06:57:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/Oe-0C7r1u5PW47MEDLEGog</id>
    <link href="https://mp.weixin.qq.com/s/Oe-0C7r1u5PW47MEDLEGog" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价希替尼治疗有EGFR 突变的局晚或转移性NSCLC安全性、PK及初步疗效的剂量递增和扩展的I期/II期临床研究</title>
    <updated>2020-12-17T06:57:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/QspalVU9PMJyuZjnXDLChw</id>
    <link href="https://mp.weixin.qq.com/s/QspalVU9PMJyuZjnXDLChw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-14T07:36:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/KrDfOjeoaybYzmiMG2HofQ</id>
    <link href="https://mp.weixin.qq.com/s/KrDfOjeoaybYzmiMG2HofQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【罗氏PD-L1招募患者28】阿替利珠单抗联合贝伐珠单抗治疗既往接受过EGFR-TKIs的非鳞状非小细胞肺癌的单组、II期研究</title>
    <updated>2020-12-14T07:36:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/6tDeOtB2Ep2vmqSWKZ5pxA</id>
    <link href="https://mp.weixin.qq.com/s/6tDeOtB2Ep2vmqSWKZ5pxA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>肿瘤病人能不能接种新冠疫苗</title>
    <updated>2020-12-13T08:32:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-13:/s/Es7aEIEkfk3V_8k7lML8vA</id>
    <link href="https://mp.weixin.qq.com/s/Es7aEIEkfk3V_8k7lML8vA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评估GNC-038在复发难治非霍奇金淋巴瘤、急淋白血病及实体瘤的安全性、PK/PD及抗瘤活性的多中心、I期临床研究</title>
    <updated>2020-12-13T08:32:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-13:/s/zXCHCyE9PVU7393UmM9FNQ</id>
    <link href="https://mp.weixin.qq.com/s/zXCHCyE9PVU7393UmM9FNQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-12T08:50:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/ubR51mtbZ_1Pp4Skjs6NRg</id>
    <link href="https://mp.weixin.qq.com/s/ubR51mtbZ_1Pp4Skjs6NRg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在食管鳞癌中比较阿替利珠单抗+TIRAGOLUMAB联合紫杉醇+顺铂作为一线治疗的III期、随机、双盲临床研究</title>
    <updated>2020-12-12T08:50:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/Jrj3YmaRHf5kmAYMZMHFPQ</id>
    <link href="https://mp.weixin.qq.com/s/Jrj3YmaRHf5kmAYMZMHFPQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募36】评价特瑞普利单抗单药治疗晚期胃或胃食管结合部腺癌的疗效和安全性的单臂、多中心II期临床研究</title>
    <updated>2020-12-11T07:59:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/4DMB6pHIZeN8XX1oncldNw</id>
    <link href="https://mp.weixin.qq.com/s/4DMB6pHIZeN8XX1oncldNw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】ASKB589注射液在局部晚期或转移性实体瘤患者中安全性、耐受性、药代动力学及抗肿瘤活性的Ⅰ/Ⅱ期临床研究</title>
    <updated>2020-12-11T07:59:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/O7OmVLG2uypyt0Gu9secCw</id>
    <link href="https://mp.weixin.qq.com/s/O7OmVLG2uypyt0Gu9secCw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-10T08:06:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/3L3XXxHYYMBDyvtUJiFtZg</id>
    <link href="https://mp.weixin.qq.com/s/3L3XXxHYYMBDyvtUJiFtZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【阿斯利康PD-L1招募患者17】评估Durvalumab联合吉西他滨加顺铂对比安慰剂联合吉西他滨加顺铂在一线晚期胆管癌的疗效</title>
    <updated>2020-12-10T08:06:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/iqZp35bPFb3uK5VkP-gCkA</id>
    <link href="https://mp.weixin.qq.com/s/iqZp35bPFb3uK5VkP-gCkA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-09T09:54:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/wyhQgUQXtISCFVdFKq6KmQ</id>
    <link href="https://mp.weixin.qq.com/s/wyhQgUQXtISCFVdFKq6KmQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】一项多中心、开放，评价西达珠单抗在晚期黑色素瘤和尿路上皮癌患者中安全性、耐受性和药代动力学的Ia/Ib期临床研究</title>
    <updated>2020-12-09T09:54:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/ORzKYH9clTuDdJvErUa71A</id>
    <link href="https://mp.weixin.qq.com/s/ORzKYH9clTuDdJvErUa71A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-08T07:49:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/K9zJD83hGtvRoP7Pg4OQ8w</id>
    <link href="https://mp.weixin.qq.com/s/K9zJD83hGtvRoP7Pg4OQ8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【辉瑞PD-1招募1】未接受过卡介苗的膀胱癌中比较PF-06801591联合 BCG一项 III 期、随机、开放、3个平行组研究</title>
    <updated>2020-12-08T07:49:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/kC7WEVyXC1Y8Ot6AghdSzA</id>
    <link href="https://mp.weixin.qq.com/s/kC7WEVyXC1Y8Ot6AghdSzA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>